Before taking the course, consult a doctor!
WEB SITE ONLY DIRECTORY. NOT PHARMACY! We do not sell medicines! None!
Description of the medicine: Idarubicin (Idarubicin)
Idarubicin.
(7S-cis) -9-Acetyl-7 - [(3-amino-2,3,6-trideoxy-α-L-lyxohexypyranosyl) oxy] -7,8,9,10-tetrahydro-6,9,11 -trioxy-5,12-naphthacenedione.
Synonym: Zavedos, Zavedos.
The structure is close to rubomycin (daunorubicin).
Produced in the form of hydrochloride.
When ingestion is rapidly absorbed into the digestive tract, bioavailability is 18-39%, C max is 2-4 h, T S is 10-35 h; In cells it turns into idarubicinol, which retains antitumor activity, is excreted by the kidneys.
Applied with lymphomas, acute myeloblastic leukemia and non-lymphocytic leukemia, lung cancer.
Assign inside and intravenously.
Intravenous adults are administered 12 mg / m 2 , children 10 mg / m 2 daily for 3 days every 3-4 weeks.
Inside appoint a dose of 30 mg / m 2 (in combination with other drugs - 15 mg / m 2 ) for 3 days every 3 weeks.
Possible side effects: granulocytopenia, thrombocytopenia, anemia, nausea, vomiting, stomatitis, abnormal liver function, alopecia, cardiotoxic effects (arrhythmias, heart failure), allergic reactions, sclerotherapy of veins after intravenous infusions).
Contraindications: heart disease, myelosuppression, dysfunction of the liver and (or) kidneys, infectious diseases, pregnancy, breast-feeding.
Forms of release: capsules to 0,005; 0.01 and 0.025 g (5, 10 and 25 mg); Powder for injection solutions in bottles of 0.005 g (5 mg).
Storage: List A.
Comments
Commenting on, remember that the content and tone of your message can hurt the feelings of real people, show respect and tolerance to your interlocutors even if you do not share their opinion, your behavior in the conditions of freedom of expression and anonymity provided by the Internet, changes Not only virtual, but also the real world. All comments are hidden from the index, spam is controlled.